In plain language
PT-141, known by the drug name bremelanotide, is an approved medicine (Vyleesi) for a specific type of low sexual desire in premenopausal women. It works through brain melanocortin receptors rather than the blood-flow pathway used by drugs like sildenafil.
What it is explored for
PT-141 stands out because it is genuinely FDA-approved as bremelanotide (Vyleesi) for low sexual desire (HSDD) in premenopausal women. What makes it interesting is its brain-based, non-hormonal approach to desire, working on arousal pathways rather than blood flow.
- Sexual desire and arousal
- Low desire in premenopausal women (FDA-approved use)
- Erectile response and sexual function
- A non-hormonal approach to libido
- Brain-based arousal pathways
- Confidence and intimacy
These are areas of active interest and reported use, not proven outcomes. This peptide carries a moderate evidence rating, see the evidence summary below for how strong the science actually is.
How it works
PT-141 is a melanocortin receptor agonist derived from the hormone alpha-MSH. Unlike erectile-dysfunction drugs, it acts on the nervous system rather than directly on blood vessels.
- Melanocortin receptor activation. Acts mainly on the MC4 receptor in the brain, which is involved in sexual arousal pathways.
- Central nervous system action. Works centrally to influence desire rather than acting directly on genital blood flow.
- Distinct from PDE5 inhibitors. Its mechanism differs from drugs such as sildenafil, which target the nitric-oxide blood-flow pathway.
The central mechanism is supported by clinical development data for the approved product.
Evidence summary
PT-141 has been through controlled clinical trials and is FDA-approved as bremelanotide for hypoactive sexual desire disorder (HSDD) in premenopausal women. In that population the effect on desire is statistically significant but modest in size. Evidence for other uses and populations is weaker.
Reported safety & side effects
As an approved drug, bremelanotide has a defined safety profile. Common side effects include nausea, flushing, and headache, and it can cause transient increases in blood pressure. It is used as an on-demand injection under medical guidance.
Frequently asked
Is PT-141 FDA-approved?
Yes, as bremelanotide (brand name Vyleesi) for hypoactive sexual desire disorder in premenopausal women. Other uses, including in men, are not approved and have weaker evidence.
How is it different from Viagra?
PT-141 acts on melanocortin receptors in the brain to influence desire, while drugs like Viagra (sildenafil) act on blood flow. They work through different pathways.